Mr. Ahmad Doroudian reports

BETTERLIFE PHARMA ANNOUNCES APPOINTMENT OF JOHN W. LAROCCA TO BOARD OF DIRECTORS AND AUDIT COMMITTEE

Betterlife Pharma Inc. has appointed John W. LaRocca, Esq., to its board of directors. Mr. LaRocca will also serve as a member of the company's audit committee.

Mr. LaRocca is a three-decade biopharmaceutical industry executive with extensive public company seasoning across the full life science life cycle, spanning generics, branded specialty pharma, commercial biotech and precommercial pipeline assets. He has served as chief legal officer, corporate secretary and founding chief compliance officer at four New York Stock Exchange- and Nasdaq-listed companies, advising boards through proxy seasons, Securities and Exchange Commission reporting cycles, contested transactions, government investigations, a U.S. Supreme Court decision, and two sell-side exits together valued at more than $1.3-billion.

In the boardroom, Mr. LaRocca has served as corporate secretary at three Nasdaq-listed public companies -- Y-mAbs Therapeutics, Aerie Pharmaceuticals and Eagle Pharmaceuticals -- where he managed the proxy process, 10-K, 10-Q and 8-K reporting cycles, Section 16 filings, at-the-market offerings, equity plan administration, and board operating practices. His experience spans mergers and acquisitions, corporate governance, securities and SEC compliance, executive compensation, enterprise risk, and health care regulatory and compliance matters -- the full range of expertise a public company audit committee relies on.

A record across mergers and acquisitions, securities, and compliance

On the transactional side, Mr. LaRocca served as principal legal officer on the $930-million sale of Aerie Pharmaceuticals to Alcon Laboratories, a Novartis subsidiary, and the $412-million sale of Y-mAbs Therapeutics to Serb Pharmaceuticals, which closed in 2025 at a 105-per-cent premium. Earlier, as deputy general counsel at Actavis, he supported the approximately $25-billion acquisition of Forest Laboratories and the approximately $8-billion acquisition of Warner Chilcott, and, over his career, has led more than 200 asset, intellectual property and product transactions across buy-side, sell-side, cross-border and postclose integration mandates.

A two-time founding chief compliance officer, at Eagle Pharmaceuticals and at Actavis, Mr. LaRocca designed publicly traded health care compliance programs from inception, aligned with the OIG's seven-element guidance, chaired enterprise risk management, and negotiated consent orders with the Federal Trade Commission and Food and Drug Administration and settlement orders with the Department of Justice and multiple state attorneys-general. He also won a landmark 5-4 U.S. Supreme Court decision in PLIVA Inc. v. Mensing, an industry-altering ruling on generic drug pre-emption, and has overseen litigation portfolios exceeding 2,500 cases and approximately $2.5-billion in aggregate risk.

"As we enter our new and exciting phase of progress, John's appointment will add significant and complementary depth and knowledge to our board. His expertise across multiple legal and regulatory channels will greatly enhance our ability to take Betterlife to much higher levels," said Ahmad Doroudian, chief executive officer of Betterlife.

"We are delighted to welcome John to our board of directors and audit committee," said Doug Drysdale, executive chairman of Betterlife. "John brings the kind of public company governance, securities, and M&A experience that is directly relevant to where Betterlife is headed. As a chief legal officer and corporate secretary at multiple Nasdaq-listed companies and as a two-time founding chief compliance officer, he has sat at the centre of the boardroom through transactions, SEC reporting cycles and complex regulatory matters. His judgment will strengthen our governance and our ability to create long-term value for shareholders."

"I am honoured to join Betterlife's board of directors and its audit committee at such an important stage in the company's development," said Mr. LaRocca. "Betterlife's approach to treating neurological disorders is compelling, and I look forward to bringing my experience in governance, securities compliance, M&A, and enterprise risk to support the board, management and shareholders as the company advances BETR-001 and executes its growth strategy."

Mr. LaRocca is the founder and principal of LaRocca Pharma Law Group/LaRocca Advisory Services, providing board advisory, fractional general counsel and chief compliance officer services to public, private-equity-backed and preinitial public offering offering life science companies. He holds a juris doctor from Columbia law school and a bachelor of arts from Columbia College, and is admitted to practise in New York and New Jersey.

Pursuant to the appointment of Mr. LaRocca as director, the company has agreed to grant Mr. LaRocca stock options to purchase 500,000 common shares of Betterlife, with an exercise price of 19 cents, quarterly vesting over 24 months and a 10-year term.

Betterlife also announces that it has received gross proceeds of $40,000 from the exercise of 350,000 share purchase warrants. The company issued 350,000 common shares in connection with the exercise of these warrants at prices of 10 cents and 15 cents. The company intends to use the gross proceeds received for continuing development of BETR-001 and working capital purposes.

About Betterlife Pharma Inc.

Betterlife is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, which is in preclinical and investigational-new-drug-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development, and is unique in that it is unregulated and therefore can be self-administered. Betterlife's synthesis patent for BETR-001 eliminates regulatory hurdles, and its pending patent, for composition and method of use, covers treatment of various neurological disorders, until around 2042. Betterlife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.

We seek Safe Harbor.